Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug ConjugateKevin J. Hamblett, Joseph A. Francisco, Kim M. Kissler et al.|Clinical Cancer Research|2004Cited by 1.2k
Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and ToxicitySvetlana O. Doronina, Peter D. Senter, Brian A. Mendelsohn et al.|Bioconjugate Chemistry|2005Cited by 511
CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancersLeia M. Smith, P. J. Carter, Albina Nesterova et al.|British Journal of Cancer|2008Cited by 289